LBA50 will highlight findings from PANKU-Breast01 (NCT06343948), a phase 3 trial evaluating izalontamab brengitecan (iza-bren) in patients with previously treated, unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer. Iza-bren is a bispecific ADC that targets both HER2 and EGFR and is conjugated to the novel topoisomerase I inhibitor payload Ed-04. Interest is high following the 2026 ASCO Annual Meeting, where the phase 3 PANKU-Breast02 trial (NCT06382142) showed a significant improvement in progression-free survival with iza-bren vs physician\u2019s choice of chemotherapy in patients with metastatic TNBC who had progressed after 1 or 2 prior lines of therapy.2<\/p>\n
Abstract 538RO will report patient-reported outcomes (PROs) from the phase 3 lidERA Breast Cancer trial (NCT04961996) of giredestrant vs standard-of-care (SOC) endocrine therapy in patients with estrogen receptor\u2013positive, HER2-negative early breast cancer. Findings presented at the 2025 San Antonio Breast Cancer Symposium showed that giredestrant significantly improved disease-free survival, with similar rates of arthralgias and hot flashes and fewer treatment discontinuations vs standard endocrine therapy.3 The PRO data will help clarify how patients feel while receiving a drug that may change the SOC for early-stage disease.<\/p>\n
Abstract 1842O will present results from the randomized phase 2 FOURLIGHT-1 study (NCT06105632) of atirmociclib (PF-07220060) plus fulvestrant (Faslodex) in patients with HR-positive, HER2-negative advanced or metastatic breast cancer who have progressed on a prior CDK4\/6 inhibitor. Patients were randomly assigned to receive atirmociclib plus fulvestrant, or fulvestrant or everolimus (Afinitor) plus exemestane, and a March 2026 news release indicated that the trial was positive.4 The data may help answer the question of whether CDK4 inhibition can improve upon the efficacy and tolerability of CDK4\/6 inhibitors, an emerging area that will require careful evaluation.<\/p>\n
On LinkedIn, respondents (n = 10) favored LBA25 (50%), followed by LBA50 and 1842O (20% each) and 538RO (10%). Results were similar on X, with respondents (n = 3) favoring LBA25 (66.7%), followed by 1842O (33.3%).<\/p>\n
Poll: What breast cancer subtype or area are you most excited to learn more about at the 2026 ESMO Congress?HR-positive breast cancerTNBCHER2-positive breast cancerBreast cancer brain metastases<\/p>\n
On LinkedIn, respondents (n = 47) favored TNBC (38%), followed by HR-positive breast cancer (30%), HER2-positive breast cancer (17%), and breast cancer brain metastases (15%). Results were more varied on X, with respondents (n = 11) favoring HR-positive breast cancer and HER2-positive breast cancer (36.4%), followed by TNBC (18.2%) and breast cancer brain metastases (9.1%).<\/p>\n
Beyond these abstracts, ESMO 2026 will include exploratory analyses in patients with baseline brain metastases. These include data from the phase 3 TROPION-Breast02 trial (NCT05374512) of first-line datopotamab deruxtecan-dlnk (Datroway) in patients with PD-L1\u2013negative metastatic TNBC, and from the phase 3 DESTINY-Breast09 trial (NCT04784715) of fam-trastuzumab deruxtecan-nxki (Enhertu) with or without pertuzumab (Perjeta) in patients with HER2-positive disease.<\/p>\n
Collectively, these presentations underscore the rapid pace of therapeutic evolution across breast cancer subtypes.<\/p>\n
ReferencesJohnston S, Martin M, O\u2019Shaughnessy J, et al. Overall survival with abemaciclib in early breast cancer. Ann Oncol. 2026;37(2):155-165. doi:10.1016\/j.annonc.2025.10.005Wu J, Zhang J, Ouyang Q, et al. Izalontamab brengitecan (iza-bren) versus physician\u2019s choice of chemotherapy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC): a randomized phase III study. J Clin Oncol. 2026;44(suppl 17):LBA1003. doi:10.1200\/JCO.2026.44.17_suppl.LBA1003Bardia A, Schmid P, Mart\u00edn M, et al. Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: results from the global phase III lidERA breast cancer trial. Presented at: 2025 San Antonio Breast Cancer Symposium; December 9-12, 2025; San Antonio, TX. Abstract GS1-10.Pfizer announces positive topline phase 2 results for next-generation CDK4 inhibitor, atirmociclib, in second-line metastatic breast cancer. News release. Pfizer. March 17, 2026. Accessed October 12, 2026. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-announces-positive-topline-phase-2-results-next <\/p>\n","protected":false},"excerpt":{"rendered":"LBA50 will highlight findings from PANKU-Breast01 (NCT06343948), a phase 3 trial evaluating izalontamab brengitecan (iza-bren) in patients with…\n","protected":false},"author":2,"featured_media":628838,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[134,111,139,69],"class_list":["post-628837","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-new-zealand","tag-newzealand","tag-nz"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/628837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=628837"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/628837\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/628838"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=628837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=628837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=628837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}